A study found that Wegovy (semaglutide), a weight-loss shot made by Novo Nordisk, helped people with alcohol addiction drink less. The finding suggests the drug might work for reducing drinking in addition to its approved uses for weight loss and diabetes.

• •Study found Wegovy (semaglutide) helped people with alcohol addiction drink less
• •Wegovy is made by Novo Nordisk and approved for weight loss and diabetes

A study found that semaglutide (Wegovy, a weight-loss injection made by Novo Nordisk) reduced how much alcohol people drank. The finding suggests the drug might help people with alcohol problems, though this wasn't its intended purpose.

• •Study found semaglutide reduced alcohol consumption in participants
• •Wegovy is Novo Nordisk's semaglutide-based weight-loss injection
• •Alcohol reduction was not the drug's intended indication

A study found that GLP-1 drugs (medicines used for weight loss) also reduced the number of days people drank heavily when they had both obesity and alcohol use disorder. This suggests GLP-1 drugs might help with drinking problems, not just weight.

• •Study links GLP-1 use to fewer heavy drinking days in patients with obesity and alcohol use disorder.
• •Findings suggest GLP-1s may have utility beyond weight loss in addiction medicine.

A study found that semaglutide (the active ingredient in Ozempic and Wegovy) may help treat alcohol use disorder in people with obesity. The research is early-stage, but it suggests the drug could have benefits beyond weight loss.

• •Study suggests semaglutide may help treat alcohol use disorder in people with obesity
• •Semaglutide is the active ingredient in Ozempic and Wegovy
• •Research is described as early-stage

Researchers at Penn Medicine found that stopping and restarting GLP-1 drugs (a type of weight-loss medicine) may make them work less well than if you keep taking them without stopping. This suggests people trying to use these drugs on-and-off to save money or manage side effects might not get the full weight-loss benefit.

• •Penn Medicine researchers studied stopping and restarting GLP-1 drugs
• •Findings suggest reduced effectiveness vs. continuous use
• •Relevant to patients cycling drugs for cost or side-effect reasons

A comparison study suggests that semaglutide (Ozempic) may preserve muscle better than tirzepatide (Mounjaro) when people use these weight-loss drugs. The finding could matter for people choosing between the two medications.

• •Comparison study suggests semaglutide preserves muscle better than tirzepatide
• •Finding relevant for patients choosing between Ozempic and Mounjaro for weight loss

A new study suggests GLP-1 drugs (a type of weight-loss medicine like Novo Nordisk's semaglutide) may help reduce heavy drinking in people. The finding opens a possible new use for these medications beyond weight loss and diabetes.

• •Study suggests GLP-1 drugs may reduce heavy drinking
• •Novo Nordisk's semaglutide cited as example GLP-1
• •Finding points to potential use beyond weight loss and diabetes

A new study looked at how tirzepatide (Mounjaro) and semaglutide (Ozempic/Wegovy) compare in terms of cost and health results for people with obesity. The research helps show which drug might be better for patients and their wallets.

• •Study compares tirzepatide (Mounjaro) vs semaglutide (Ozempic/Wegovy) in obesity
• •Analysis covers both cost and health outcomes

• •Peptide-drug conjugate reported to hit 5 obesity targets
• •Coverage published by C&EN under peptide therapy research

A new article suggests that semaglutide (Ozempic, Zepbound) may work partly by reducing inflammation in the body, not just by helping people feel less hungry. This anti-inflammatory effect could explain some of the drug's health benefits beyond weight loss.

• •Scientific American piece highlights anti-inflammatory effects of semaglutide and tirzepatide
• •Mechanism proposed beyond appetite suppression
• •Frames inflammation reduction as driver of health benefits

• •Procedure for type 2 diabetes reported to help maintain weight loss after GLP-1 discontinuation

• •Study reports a link between GLP-1 drugs and hair loss

• •HSS studies provide early evidence on perioperative considerations for patients on GLP-1 medications

BPC-157, a peptide being studied for various health uses, is gaining attention as research explores new potential applications. The article reviews the expanding scientific interest in this peptide compound.

• •BPC-157 is being studied for various health applications
• •Article frames the peptide as having expanding research horizons